Compare Abbott Laboratories (ABT) vs Boeing Co (BA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Boeing Co — how do they compare? Abbott Laboratories trades at $95.17 (market cap $166.94B), while Boeing Co trades at $224.59 (market cap $182.63B). The key difference: Abbott Laboratories and Boeing Co are close in size by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | BA | |
|---|---|---|
Market Cap | $166.94B | $182.63B |
Sector | Health | Industrials |
52-Week High | $136.62 | $252.15 |
52-Week Low | $82.57 | $179.12 |
Enterprise Value | $193.69B | $208.94B |
Dividend Yield | 2.63% | 0.03% |
Volume | — | 7,591,579 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Boeing (BA) trades at $231.68, up 2.29% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $268.33. The company returned to profitability in 2025 with $2.24B net income on $89.46B revenue, though valuation ratios like P/E of 92.7 remain elevated. Recent news highlights defense contract wins and production expansion, including a new 737 assembly line.
Outlook: Boeing's recovery trajectory offers upside potential driven by operational improvements and strong backlog, but high debt, thin margins, and execution risks pose challenges. Analyst sentiment is predominantly bullish, yet investors should weigh valuation concerns against growth catalysts in the aerospace cycle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Boeing Co
The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.
Read more on BA →
